230 related articles for article (PubMed ID: 35229619)
1. Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review.
Ravalli F; Vela Parada X; Ujueta F; Pinotti R; Anstrom KJ; Lamas GA; Navas-Acien A
J Am Heart Assoc; 2022 Mar; 11(6):e024648. PubMed ID: 35229619
[TBL] [Abstract][Full Text] [Related]
2. Evaluation on curative effects of ethylene diamine tetra-acetic acid chelation therapy in treating with atherosclerotic cardiovascular disease: A protocol for systematic review and meta-analysis.
Song T; Zhang D
Medicine (Baltimore); 2020 Dec; 99(52):e23346. PubMed ID: 33350725
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Chelation therapy in the treatment of cardiovascular diseases.
Ibad A; Khalid R; Thompson PD
J Clin Lipidol; 2016; 10(1):58-62. PubMed ID: 26892121
[TBL] [Abstract][Full Text] [Related]
5. Chelation therapy for atherosclerotic cardiovascular disease.
Villarruz MV; Dans A; Tan F
Cochrane Database Syst Rev; 2002; (4):CD002785. PubMed ID: 12519577
[TBL] [Abstract][Full Text] [Related]
6. EDTA chelation therapy for cardiovascular disease: a systematic review.
Seely DM; Wu P; Mills EJ
BMC Cardiovasc Disord; 2005 Nov; 5():32. PubMed ID: 16262904
[TBL] [Abstract][Full Text] [Related]
7. EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes.
Ouyang P; Gottlieb SH; Culotta VL; Navas-Acien A
Curr Cardiol Rep; 2015 Nov; 17(11):96. PubMed ID: 26364188
[TBL] [Abstract][Full Text] [Related]
8. Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2).
Navas-Acien A; Santella RM; Joubert BR; Huang Z; Lokhnygina Y; Ujueta F; Gurvich I; LoIacono NJ; Ravalli F; Ward CD; Jarrett JM; Salazar AL; Boineau R; Jones TLZ; Mark DB; Newman JD; Nathan DM; Anstrom KJ; Lamas GA
Am Heart J; 2024 Jul; 273():72-82. PubMed ID: 38621575
[TBL] [Abstract][Full Text] [Related]
9. Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trial.
Mark DB; Anstrom KJ; Clapp-Channing NE; Knight JD; Boineau R; Goertz C; Rozema TC; Liu DM; Nahin RL; Rosenberg Y; Drisko J; Lee KL; Lamas GA;
Circ Cardiovasc Qual Outcomes; 2014 Jul; 7(4):508-16. PubMed ID: 24987051
[TBL] [Abstract][Full Text] [Related]
10. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
11. EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment.
Born T; Kontoghiorghe CN; Spyrou A; Kolnagou A; Kontoghiorghes GJ
Toxicol Mech Methods; 2013 Jan; 23(1):11-7. PubMed ID: 22991933
[TBL] [Abstract][Full Text] [Related]
12. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT).
Ujueta F; Arenas IA; Escolar E; Diaz D; Boineau R; Mark DB; Golden P; Lindblad L; Kim H; Lee KL; Lamas GA
J Diabetes Complications; 2019 Jul; 33(7):490-494. PubMed ID: 31101487
[TBL] [Abstract][Full Text] [Related]
13. Chelation therapy in cardiovascular disease: an update.
Sultan S; Murarka S; Jahangir A; Mookadam F; Tajik AJ; Jahangir A
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):843-854. PubMed ID: 28597699
[TBL] [Abstract][Full Text] [Related]
14. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.
Lamas GA; Goertz C; Boineau R; Mark DB; Rozema T; Nahin RL; Lindblad L; Lewis EF; Drisko J; Lee KL;
JAMA; 2013 Mar; 309(12):1241-50. PubMed ID: 23532240
[TBL] [Abstract][Full Text] [Related]
15. Role of EDTA chelation therapy in cardiovascular diseases.
Shrihari JS; Roy A; Prabhakaran D; Reddy KS
Natl Med J India; 2006; 19(1):24-6. PubMed ID: 16570682
[TBL] [Abstract][Full Text] [Related]
16. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients.
Peguero JG; Arenas I; Lamas GA
Trends Cardiovasc Med; 2014 Aug; 24(6):232-40. PubMed ID: 25106084
[TBL] [Abstract][Full Text] [Related]
17. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT).
Escolar E; Lamas GA; Mark DB; Boineau R; Goertz C; Rosenberg Y; Nahin RL; Ouyang P; Rozema T; Magaziner A; Nahas R; Lewis EF; Lindblad L; Lee KL
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):15-24. PubMed ID: 24254885
[TBL] [Abstract][Full Text] [Related]
18. A TACTful reappraisal of chelation therapy in cardiovascular disease.
Sidhu MS; Saour BM; Boden WE
Nat Rev Cardiol; 2014 Mar; 11(3):180-3. PubMed ID: 24343569
[TBL] [Abstract][Full Text] [Related]
19. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
